

Clinical Validation Report of COVID-19 Ag Rapid Saliva Test Device

Product name: COVID-19 Ag Rapid Saliva Test Device

Cat#: CO-07

Manufacturer: Jiangsu Well Biotech Co., Ltd.



1. Background information for clinical evaluation

The SARS-CoV-2 belong to the genus Nestovirus, Coronaviridae, and is divided into threegenera:α,β,andy.Thegenusαandβareonlypathogenictomammals.COVID-

19isanacuterespiratoryinfectious disease infected with SARS-CoV-2. Currently, the patients infected by the novel coronavirus are the main source of infection; asymptomatic infected people can also be an infectious source. Based on the current epidemiological investigation, the incubation period is 1 to 14 days, mostly 3 to 7 days.

Themainmanifestationsincludefever, fatigue and drycough. Nasal congestion, runny nose, sore throat, myalgia and diarrhea are found in a few cases.

The COVID-19 Ag Rapid Saliva Test Device developed by Jiangsu Well Biotech Co., Ltd. is a rapid chromatographic immunoassay for the qualitative detection of specific antigens to SARS-CoV-2 present in human saliva. The test provides more convenient technical support for timely blocking the spread of the virus.

2. Testpurposes

To verify the accuracy and the reliability of the COVID-19 Ag Rapid Saliva Test Device produced by Jiangsu Well Biotech Co., Ltd. using the clinical specimen.

3. Testdesign

3.1 Testplan

COVID-19AgRapidSalivaTestDevicesareusedtoconductcomparativeresearch testsonclinicallysuspectedCOVID-19,andtoprovethattheCOVID-19AgRapid Saliva Test can be used to detect antigen in the patient with the SAR-Cov-2 infection with symptom onset of first 7 days. The test results will be compared to reference PCR (BGI Genomics Co., Ltd.)results.

3.2 TestingSite

3.2.1 Jiangsu Provincial Center for Disease Control and Prevention

Director: Zhu Fengcai, Operators: Tan zhongmin, Baochangjun

3.2.2 Kangwon National University Hospital (Korea)

Director: Dr. Lee, Operators: SueKim

3.3 Samplerequired

The total number of clinical trials of this product should not less than 150 cases. The samples are classified into the potential positive group (symptomatic and asymptomatic) and the negative group (asymptomatic) as per the test results of the



reference PCR. All sample were collected either from hospitalized COVID-19 patients or during routine hospital visits.

Enrollment criteria: Clinical background information should be complete and traceable.

The test results of both the COVID-19 Ag Rapid SalivaTest Device and the reference PCR method shall be compared with statistical analysis.

The reference method is PCR for SARS-CoV-2 nucleic acids in nasal swabs and/or bronchoalveolar lavage fluid (BALF). The name of the PCR test: Real-Time Fluorescent RT-PCR Kit for Detecting SARS-nCoV-2.

The manufacture information of PCR test: BGI Genomics Co.,Ltd.

LOD:100copies/mL

3.4 Sample collection and storage

Sample collection: human saliva has been demonstrated suitable for COVID-19 Ag Rapid SalivaTest Device in the bench study. This test is designed for one step test for COVID-19 antigen in human saliva. Please following the sample collection procedure described in the instruction for use (IFU).

Sample storage: NA

4. In vitro diagnostic reagents and reference products fortesting

4.1 Test in vitro diagnostic reagents

Name: COVID-19 Ag Rapid SalivaTest

Cat#: CO-07

LOT: 2012031

Expiry: Dec, 2022

StorageConditions:Store in a dry place at 2-30°C, protected from light. Remove the test device from the sealed pouch and use the device as soon as possible.Best results will be obtained if the assay is performed immediately after opening the foil pouch.

Manufacture: Jiangsu Well Biotech Co., Ltd.

4.2 Referencereagents

The reference method is PCR, SARS-CoV-2 nucleic acids in nasal swabs from swab samples. The name of the PCR test: Real-Time Fluorescent RT-PCR Kit for Detecting SARS-nCoV-2.



The manufacture: BGI Genomics Co., Ltd. LOD:100copies/mL

5. Experimentmethod

- **5.1** Following product instruction, A total of 330 samples including 200 negatives and 130 positives from patients hospitalized or routine visit with symptom onset within 7 days, who were confirmed with PCR referencemethod.
- **5.2** Each sample was blind labeled and tested using PCR referencetest in randomorder.
- **5.3** Donors shall collected his/her saliva sample using COVID-19 Ag Rapid SalivaTest Device at the same day as the PCR tested sample.
- **5.4** The saliva sample collecting and testing procedure follows below. For details, please refer to the product instruction:
 - Allow the test device to reach room temperature 15 30°C, and instruct the user not to eat, drink, smoke or chew tobacco products for at least 10 minutes prior to use the test.
 - **Step 1:** Remove the test device from the sealed pouch and use the device as soon as possible.Best results will be obtained if the assay is performed immediately after opening the foil pouch.
 - **Step 2:**Cough deeply twice before collecting the samples.
 - Step 3:Pull the blue cap off gently by holding the sides to expose the collection pad.
 - **Step 4:**Hold the top portion of the device and place the collection pad into the mouth.
 - **Step 5:** Rub the collection pad against the cheek and tongue gently in a circular motion about 10 times. And then place the collection pad in the mouth for about 1~2 minutes until the C line show up in the C region.
 - **Step 6:** Remove the device from mouth as soon as the C line appears at the C rigion.
 - Step 7: Place the cap onto the device, lay it on a flat surface.
 - **Step 8:**Read results at 10-15minutes after removing device from mouth. Do not read results after 20 minutes.

6. Statistical methods of statistical analysis of clinical researchdata

6.1 Methods evaluating clinical performance

Whether various indexes can reach the standards of clinical evaluation shall be judgedbycalculatingtheconsistencypercentageofnegative/positiveandthetotal consistency percentage in the test results of the product tested and the reference product, to validate the accuracy and applicability of the product in clinical applications. The determination results of both products shall be compared. The test results recorded shall be subject to statistical analysis upon completion of determination of all clinical samples, to calculate the consistency percentage of



negative/positiveandthetotalconsistencypercentage.Afterwards,equivalenceof both shall be evaluated as per these statisticalindexes.

6.2 Statisticalmethod

The products launched on the market shall be subject to comparative study and evaluation. Each sample shall be tested with the product and the reference PCR product respectively, and then the consistency in statistical results of these two inspection methods shall be compared through Kappain spection.

ThedatashallbesubjectedtoKappainspectionandanalysisandtheKappa coefficient shall be calculated. Favorable consistency can be proven if Kappais > 0.8. The consistency in test results of the product and the reference PCR product are evaluated as per the evaluation standards.

7. Criteria of clinicalevaluation

The coincidence rate shall be calculated by comparing with the reference product. The product performance shall meet the following requirements.

Coincidence rate of negative: More than 90% of the samples tested should indicate negative results for both the product and the reference PCR product.

Coincidence rate of positive: More than 90% of the samples tested should indicate positive results for both the product and the reference PCR product.

8. Provisions for amendments to clinical validation

In general, the clinical validation protocol should not be changed. Any modification to the project during the test must be documented and explained. The time, reason for the change, process of the change, and whether there is a record of the change needtobe explained in detail and its impact on the entire research result explained.

There was no change in protocol during this clinical evaluation.

9. Results and Analysis of ClinicalTests

In total, 200 normal negative and 130 potential positive symptomatic and asymptomatic patient candidates saliva and nasal swab samples were used in this clinical evaluation. The samples include different gender and age. Most positive sample tested are in early stage of infection.

The test results are summarized in the table below:



| | | COVID-19 Ag Ra | pid Saliva Test Device | |
|----------|--------|----------------|------------------------|-----|
| | | - | Total Result | |
| | + | 125 | 5 | 130 |
| PCR | _ | 0 | 200 | 200 |
| Total Re | esults | 125 | 205 | 330 |

As summarized in the above table, all 200 negative specimens gave negative results; out of 130 positive specimens, 125 shown antigen positive, The result shows:

Relative sensitivity: 125/130= 96.15% (95%CI 91.31%~98.35%)

Relative specificity: 200/200 >99% (95%CI 98.12%~100%)

Overall agreement: (125+200)/(125+0+5+200)*100%=98.48% (95%CI

96.50%~99.35%)

CI: Confidence Interval

Kappa=0.97

Agreement of different Ct value interval was summarized and analyzed, see Table 2.

Table 2.Relation of PPA to Ct values

| Ctvalue interval | PCR | COVID-19 Ag Rapid Saliva Test Device | PPA |
|------------------------|-----|---|------|
| RdRP Ctvalue < 30 | 105 | 105+ | 100% |
| Ngene Ctvalue<30 | 105 | 105+ | 100% |
| 30≤RdRP Ct value <36 | 20 | 20+ | 100% |
| 30≤N gene Ct value <36 | 25 | 20+ , 5- | 80% |

10. Analysis on consistency in TestResults

According to the test result, there are 325 samples showing the consistency results for rapid test and RT-PCR. For qualitative rapid test, the result will show positive, negative and invalid, for RT-PCR detection, the Ct value will indicate the result, Ct value>40 means the detection result is negative.

In our validation test, the amountofRdRPCtvaluebelow40is125, the amountofNgeneCtvaluebelow40is130, the amountofbothRdRPandNgeneCtvalueareallbelow40is125.Themedianof RdRP Ct value is 20.47, while the N gene Ctvalue is20.06.



Table 3. The consistency in TestResult

| | RdRP Ct va | alue data below 40) | valu | N gene ue | Ct |
|-------|--------------|------------------------|-------|------------------------|--------|
| (10 | nai 01 120 v | adia solow 10) | | Total of 130 ow 40) | 0 data |
| Maxim | Minim | Median | Maxim | Minim | Medi |
| um | um | | um | um | an |
| 35.3 | 14.2 | 20.47 | 35.4 | 14.0 | 20. |
| 1 | 5 | | 6 | 1 | 06 |

11. Analysis on Inconsistency in Test Results

5 confirmed by PCR positive samples, showed Antigen negative. This may due to the insufficient of sample collected.

Table 4: The Inconsistency in TestResult

| Carranta ID | Λ | O a ra da ra | COVID-19 | PCR | | | |
|-------------|-----|--------------|----------|------|--------|--|--|
| Sample ID | Age | Gender | Ag Test | RdRP | N gene | | |
| NS257 | 34 | F | - | >40 | 34.28 | | |
| NS262 | 39 | F | - | >40 | 34.15 | | |
| NS304 | 32 | M | - | >40 | 32.29 | | |
| NS314 | 22 | M | - | >40 | 34.22 | | |
| NS329 | 42 | M | - | >40 | 34.21 | | |

12. Discussion and Conclusions

12.1 Discussion

Results of comparative analysis of the product tested and the reference product:

Test results of the antigen test and the reference PCR product: both the coincidence rate of negative/positive are larger than 90%, indicating favorable consistency with the reference PCR product. In the analysis results of Kappa inspection, Kappa was proven >0.8, indicating favorable and high consistency of both methods. Both systems were considered equivalent.

12.2 Testconclusions

ByanalyzingthetestresultsoftheproducttestedandthePCRreferenceproduct, the consistency percentage of negative/positive is proven high. Moreover, according to the results of statistical analysis, there is no remarkable difference in test results of both, indicating favorable consistency in diagnosis and equivalence of two such systems. Therefore, such product is applicable to qualitative clinical analysis on the SARS-CoV-2 antigen in the human saliva, and can be used for auxiliary diagnosis



of those suffering from pneumonia triggered by COVID-19.

13. Quality controlmethods

13.1 On-site qualitycontrol

The entire clinical evaluation is conducted under strict operation, and the test content is complete and authentic. All observations and findings in the clinical trialshave been verified and the data are reliable. The conclusions in the clinical trials are derived from the original data.

13.2 Quality control of clinical experimentprocess

During the evaluation, quality control was performed daily to ensure that the product was under control. Strict quality control is performed to ensure the quality of the clinical testing.

14. Prediction of adverseevents

The COVID-19 AgRapid Saliva Test Device is an invitrodiagnostic test and the test results are only used for comparative studies. It involves personal privacy, does not serve as a basis for auxiliary diagnosis, does not bring any risk to the subject.

15. References

- 1. The "Technical Review Points for the Registration of New Coronavirus Antigen / Antibody Detection Reagents in 2019 (Trial)" issued by the State Drug Administration Medical Device Technical Evaluation Center on February 25,2020,
- 2. "Pneumonitis Diagnosis and Treatment Program for New Coronavirus Infection (Trial Version 6)" issued by the National Health Committee on February 19,2020.



Annex 1: Package Insert

Attached



Annex 2: The Data of Clinical Sample Tests

| SampleID | ٨٠٠ | Candar | COVID-19 | PC | CR | SampleID | Λ | Gender | COVID-19 | P | CR |
|----------|-----|--------|----------|------|--------|----------|-----|--------|----------|------|--------|
| | Age | Gender | Ag Test | RdRP | N gene | | Age | Gender | Ag Test | RdRP | N gene |
| NS1 | 42 | F | - | >40 | >40 | NS101 | 28 | F | - | >40 | >40 |
| NS2 | 39 | М | - | >40 | >40 | NS102 | 29 | М | - | >40 | >40 |
| NS3 | 40 | М | - | >40 | >40 | NS103 | 48 | F | - | >40 | >40 |
| NS4 | 17 | F | - | >40 | >40 | NS104 | 44 | М | - | >40 | >40 |
| NS5 | 26 | М | - | >40 | >40 | NS105 | 61 | F | - | >40 | >40 |
| NS6 | 23 | F | - | >40 | >40 | NS106 | 29 | М | - | >40 | >40 |
| NS7 | 16 | М | - | >40 | >40 | NS107 | 57 | F | - | >40 | >40 |
| NS8 | 43 | F | - | >40 | >40 | NS108 | 32 | М | - | >40 | >40 |
| NS9 | 51 | М | - | >40 | >40 | NS109 | 54 | М | - | >40 | >40 |
| NS10 | 22 | М | - | >40 | >40 | NS110 | 71 | F | - | >40 | >40 |
| NS11 | 45 | F | - | >40 | >40 | NS111 | 28 | F | - | >40 | >40 |
| NS12 | 34 | F | - | >40 | >40 | NS112 | 29 | М | - | >40 | >40 |
| NS13 | 61 | F | - | >40 | >40 | NS113 | 48 | F | - | >40 | >40 |
| NS14 | 54 | М | - | >40 | >40 | NS114 | 44 | М | - | >40 | >40 |
| NS15 | 34 | F | - | >40 | >40 | NS115 | 61 | F | - | >40 | >40 |
| NS16 | 23 | М | - | >40 | >40 | NS116 | 29 | М | - | >40 | >40 |
| NS17 | 22 | М | - | >40 | >40 | NS117 | 57 | F | - | >40 | >40 |
| NS18 | 20 | F | - | >40 | >40 | NS118 | 32 | М | - | >40 | >40 |
| NS19 | 18 | М | - | >40 | >40 | NS119 | 42 | F | - | >40 | >40 |
| NS20 | 16 | F | - | >40 | >40 | NS120 | 45 | F | - | >40 | >40 |

| NS21 | 14 | М | - | >40 | >40 | NS121 | 36 | М | - | >40 | >40 |
|------|----|---|---|-----|-----|-------|----|---|---|-----|-----|
| NS22 | 19 | F | - | >40 | >40 | NS122 | 15 | F | - | >40 | >40 |
| NS23 | 20 | М | - | >40 | >40 | NS123 | 17 | М | 1 | >40 | >40 |
| NS24 | 27 | М | - | >40 | >40 | NS124 | 42 | F | - | >40 | >40 |
| NS25 | 26 | F | - | >40 | >40 | NS125 | 45 | F | - | >40 | >40 |
| NS26 | 25 | F | - | >40 | >40 | NS126 | 36 | М | - | >40 | >40 |
| NS27 | 28 | F | - | >40 | >40 | NS127 | 15 | F | - | >40 | >40 |
| NS28 | 29 | М | - | >40 | >40 | NS128 | 17 | М | - | >40 | >40 |
| NS29 | 48 | F | - | >40 | >40 | NS129 | 16 | F | - | >40 | >40 |
| NS30 | 44 | М | - | >40 | >40 | NS130 | 54 | М | - | >40 | >40 |
| NS31 | 61 | F | - | >40 | >40 | NS131 | 43 | F | - | >40 | >40 |
| NS32 | 29 | М | - | >40 | >40 | NS132 | 72 | М | - | >40 | >40 |
| NS33 | 57 | F | - | >40 | >40 | NS133 | 49 | F | - | >40 | >40 |
| NS34 | 32 | М | - | >40 | >40 | NS134 | 42 | F | - | >40 | >40 |
| NS35 | 54 | М | - | >40 | >40 | NS135 | 45 | F | - | >40 | >40 |
| NS36 | 71 | F | - | >40 | >40 | NS136 | 42 | F | - | >40 | >40 |
| NS37 | 34 | М | - | >40 | >40 | NS137 | 45 | F | - | >40 | >40 |
| NS38 | 42 | F | - | >40 | >40 | NS138 | 36 | М | - | >40 | >40 |
| NS39 | 45 | F | - | >40 | >40 | NS139 | 55 | F | - | >40 | >40 |
| NS40 | 36 | М | - | >40 | >40 | NS140 | 17 | М | - | >40 | >40 |
| NS41 | 65 | F | - | >40 | >40 | NS141 | 16 | F | - | >40 | >40 |
| NS42 | 37 | М | - | >40 | >40 | NS142 | 64 | М | - | >40 | >40 |
| NS43 | 56 | F | - | >40 | >40 | NS143 | 53 | F | - | >40 | >40 |

| NS44 | 44 | М | - | >40 | >40 | NS144 | 12 | М | - | >40 | >40 |
|------|----|---|---|-----|-----|-------|----|---|---|-----|-----|
| NS45 | 53 | F | - | >40 | >40 | NS145 | 42 | F | - | >40 | >40 |
| NS46 | 22 | М | - | >40 | >40 | NS146 | 45 | F | - | >40 | >40 |
| NS47 | 19 | F | - | >40 | >40 | NS147 | 36 | М | - | >40 | >40 |
| NS48 | 28 | F | - | >40 | >40 | NS148 | 42 | F | - | >40 | >40 |
| NS49 | 29 | М | - | >40 | >40 | NS149 | 45 | F | - | >40 | >40 |
| NS50 | 48 | F | - | >40 | >40 | NS150 | 36 | M | - | >40 | >40 |
| NS51 | 44 | М | - | >40 | >40 | NS151 | 15 | F | - | >40 | >40 |
| NS52 | 61 | F | - | >40 | >40 | NS152 | 17 | M | - | >40 | >40 |
| NS53 | 29 | М | - | >40 | >40 | NS153 | 16 | F | - | >40 | >40 |
| NS54 | 57 | F | - | >40 | >40 | NS154 | 14 | М | - | >40 | >40 |
| NS55 | 32 | М | - | >40 | >40 | NS155 | 13 | F | - | >40 | >40 |
| NS56 | 54 | М | - | >40 | >40 | NS156 | 12 | M | - | >40 | >40 |
| NS57 | 71 | F | - | >40 | >40 | NS157 | 42 | F | - | >40 | >40 |
| NS58 | 42 | F | - | >40 | >40 | NS158 | 42 | F | - | >40 | >40 |
| NS59 | 45 | F | - | >40 | >40 | NS159 | 46 | F | - | >40 | >40 |
| NS60 | 36 | М | - | >40 | >40 | NS160 | 36 | М | - | >40 | >40 |
| NS61 | 15 | F | - | >40 | >40 | NS161 | 54 | F | - | >40 | >40 |
| NS62 | 17 | М | - | >40 | >40 | NS162 | 23 | М | - | >40 | >40 |
| NS63 | 63 | F | - | >40 | >40 | NS163 | 16 | F | - | >40 | >40 |
| NS64 | 34 | М | - | >40 | >40 | NS164 | 34 | М | - | >40 | >40 |
| NS65 | 23 | F | - | >40 | >40 | NS165 | 53 | F | - | >40 | >40 |
| NS66 | 22 | М | - | >40 | >40 | NS166 | 34 | М | - | >40 | >40 |

| NS67 | 19 | F | - | >40 | >40 | NS167 | 42 | F | - | >40 | >40 |
|------|----|---|---|-----|-----|-------|----|---|---|-----|-----|
| NS68 | 42 | F | - | >40 | >40 | NS168 | 42 | F | - | >40 | >40 |
| NS69 | 45 | F | - | >40 | >40 | NS169 | 45 | F | - | >40 | >40 |
| NS70 | 36 | М | - | >40 | >40 | NS170 | 36 | М | - | >40 | >40 |
| NS71 | 15 | F | - | >40 | >40 | NS171 | 35 | F | - | >40 | >40 |
| NS72 | 23 | М | - | >40 | >40 | NS172 | 67 | М | - | >40 | >40 |
| NS73 | 32 | F | - | >40 | >40 | NS173 | 66 | F | - | >40 | >40 |
| NS74 | 54 | М | - | >40 | >40 | NS174 | 44 | М | - | >40 | >40 |
| NS75 | 53 | F | - | >40 | >40 | NS175 | 63 | F | - | >40 | >40 |
| NS76 | 32 | М | - | >40 | >40 | NS176 | 22 | M | - | >40 | >40 |
| NS77 | 19 | F | - | >40 | >40 | NS177 | 42 | F | - | >40 | >40 |
| NS78 | 42 | F | - | >40 | >40 | NS178 | 46 | F | - | >40 | >40 |
| NS79 | 45 | F | - | >40 | >40 | NS179 | 37 | M | - | >40 | >40 |
| NS80 | 36 | М | - | >40 | >40 | NS180 | 18 | F | - | >40 | >40 |
| NS81 | 15 | F | - | >40 | >40 | NS181 | 25 | М | - | >40 | >40 |
| NS82 | 65 | М | - | >40 | >40 | NS182 | 16 | F | - | >40 | >40 |
| NS83 | 46 | F | - | >40 | >40 | NS183 | 45 | М | - | >40 | >40 |
| NS84 | 34 | М | - | >40 | >40 | NS184 | 43 | F | - | >40 | >40 |
| NS85 | 53 | F | - | >40 | >40 | NS185 | 65 | М | - | >40 | >40 |
| NS86 | 72 | М | - | >40 | >40 | NS186 | 42 | F | - | >40 | >40 |
| NS87 | 19 | F | - | >40 | >40 | NS187 | 45 | F | - | >40 | >40 |
| NS88 | 42 | F | - | >40 | >40 | NS188 | 36 | М | - | >40 | >40 |
| NS89 | 45 | F | - | >40 | >40 | NS189 | 15 | F | - | >40 | >40 |

| NS90 | 37 | М | - | >40 | >40 | NS190 | 17 | М | - | >40 | >40 |
|-------|----|---|---|-------|-------|-------|----|---|---|-------|-------|
| NS91 | 25 | F | - | >40 | >40 | NS191 | 46 | F | - | >40 | >40 |
| NS92 | 57 | М | - | >40 | >40 | NS192 | 14 | М | - | >40 | >40 |
| NS93 | 36 | F | - | >40 | >40 | NS193 | 63 | F | - | >40 | >40 |
| NS94 | 56 | М | - | >40 | >40 | NS194 | 29 | М | - | >40 | >40 |
| NS95 | 53 | F | - | >40 | >40 | NS195 | 42 | F | - | >40 | >40 |
| NS96 | 32 | М | - | >40 | >40 | NS196 | 45 | F | - | >40 | >40 |
| NS97 | 19 | F | - | >40 | >40 | NS197 | 36 | М | - | >40 | >40 |
| NS98 | 42 | F | - | >40 | >40 | NS198 | 35 | F | - | >40 | >40 |
| NS99 | 45 | F | - | >40 | >40 | NS199 | 57 | М | - | >40 | >40 |
| NS100 | 36 | М | - | >40 | >40 | NS200 | 26 | F | - | >40 | >40 |
| NS201 | 47 | М | + | 16.29 | 15.96 | NS219 | 57 | F | + | 26.2 | 25.94 |
| NS202 | 46 | F | + | 14.42 | 14.01 | NS220 | 32 | М | + | 30.84 | 30.22 |
| NS203 | 34 | М | + | 27.24 | 27.78 | NS221 | 54 | M | + | 27.18 | 27.65 |
| NS204 | 23 | F | + | 31.24 | 30.93 | NS222 | 71 | F | + | 20.14 | 21.32 |
| NS205 | 52 | М | + | 14.65 | 14.73 | NS223 | 42 | F | + | 25.84 | 26.12 |
| NS206 | 28 | F | + | 31.76 | 31.44 | NS224 | 45 | F | + | 34.17 | 35.46 |
| NS207 | 42 | F | + | 22.90 | 23.45 | NS225 | 36 | М | + | 25.68 | 25.68 |
| NS208 | 45 | F | + | 22.65 | 23.10 | NS226 | 35 | F | + | 20.14 | 19.74 |
| NS209 | 36 | М | + | 22.94 | 22.71 | NS227 | 17 | М | + | 35.12 | 34.21 |
| NS210 | 17 | М | + | 31.85 | 31.55 | NS228 | 56 | F | + | 27.18 | 27.45 |
| NS211 | 57 | F | + | 34.86 | 33.76 | NS229 | 77 | М | + | 23.49 | 23.42 |
| NS212 | 32 | М | + | 14.25 | 14.39 | NS230 | 16 | F | + | 22.87 | 23.09 |

| NS213 | 54 | М | + | 31.76 | 31.44 | NS231 | 34 | M | + | 20.14 | 19.74 |
|-------|----|---|---|-------|-------|-------|----|---|---|-------|-------|
| NS214 | 71 | F | + | 24.09 | 24.57 | NS232 | 33 | F | + | 19.34 | 19.34 |
| NS215 | 42 | F | + | 27.34 | 26.79 | NS233 | 42 | М | + | 30.21 | 30.42 |
| NS216 | 45 | F | + | 19.24 | 19.43 | NS234 | 19 | F | + | 24.64 | 24.15 |
| NS217 | 36 | М | + | 27.18 | 26.91 | NS235 | 42 | F | + | 18.43 | 18.25 |
| NS218 | 15 | F | + | 19.39 | 19.51 | NS236 | 33 | F | + | 19.47 | 19.29 |
| NS237 | 54 | М | + | 31.76 | 31.44 | NS254 | 55 | М | + | 20.14 | 19.74 |
| NS238 | 71 | F | + | 24.09 | 24.57 | NS255 | 53 | F | + | 19.34 | 19.34 |
| NS239 | 42 | F | + | 27.34 | 26.79 | NS256 | 24 | М | + | 33.01 | 33.21 |
| NS240 | 45 | F | + | 19.24 | 19.43 | NS257 | 34 | F | - | >40 | 34.28 |
| NS241 | 36 | М | + | 27.18 | 26.91 | NS258 | 45 | F | + | 18.43 | 18.25 |
| NS242 | 54 | М | + | 31.76 | 31.44 | NS259 | 64 | М | + | 20.14 | 19.74 |
| NS243 | 71 | F | + | 24.09 | 24.57 | NS260 | 43 | F | + | 19.34 | 19.34 |
| NS244 | 42 | М | + | 27.34 | 26.79 | NS261 | 52 | M | + | 23.21 | 23.16 |
| NS245 | 45 | F | + | 19.24 | 19.43 | NS262 | 39 | F | - | >40 | 34.15 |
| NS246 | 36 | М | + | 27.18 | 26.91 | NS263 | 62 | F | + | 18.43 | 18.25 |
| NS247 | 54 | М | + | 31.76 | 31.44 | NS264 | 74 | M | + | 20.14 | 19.74 |
| NS248 | 71 | М | + | 24.09 | 24.57 | NS265 | 56 | F | + | 19.34 | 19.34 |
| NS249 | 42 | F | + | 27.34 | 26.79 | NS266 | 76 | M | + | 23.91 | 24.21 |
| NS250 | 45 | F | + | 19.24 | 19.43 | NS267 | 59 | F | + | 24.64 | 24.15 |
| NS251 | 36 | М | + | 27.18 | 26.91 | NS268 | 46 | F | + | 18.43 | 18.25 |
| NS252 | 54 | М | + | 31.76 | 31.44 | NS269 | 64 | M | + | 20.14 | 19.74 |
| NS253 | 71 | F | + | 24.09 | 24.57 | NS270 | 63 | F | + | 19.34 | 19.34 |

| NS271 | 42 | F | + | 27.34 | 26.79 | NS294 | 22 | M | + | 35.31 | 34.25 |
|-------|----|---|---|-------|-------|-------|----|---|---|-------|-------|
| NS272 | 45 | F | + | 19.24 | 19.43 | NS295 | 18 | F | + | 24.64 | 24.15 |
| NS273 | 36 | М | + | 27.18 | 26.91 | NS296 | 43 | F | + | 18.43 | 18.25 |
| NS274 | 54 | М | + | 31.76 | 31.44 | NS297 | 24 | М | + | 20.14 | 19.74 |
| NS275 | 72 | F | + | 24.09 | 24.57 | NS298 | 43 | F | + | 19.34 | 19.34 |
| NS276 | 43 | F | + | 27.34 | 26.79 | NS299 | 22 | М | + | 18.23 | 18.25 |
| NS277 | 45 | М | + | 19.24 | 19.43 | NS300 | 59 | М | + | 24.64 | 24.15 |
| NS278 | 46 | М | + | 27.18 | 26.91 | NS301 | 42 | F | + | 18.43 | 18.25 |
| NS279 | 54 | М | + | 31.76 | 31.44 | NS302 | 54 | М | + | 20.14 | 19.74 |
| NS280 | 71 | F | + | 24.09 | 24.57 | NS303 | 53 | F | + | 19.34 | 19.34 |
| NS281 | 45 | М | + | 27.34 | 26.79 | NS304 | 32 | М | + | >40 | 32.29 |
| NS282 | 43 | F | + | 19.24 | 19.43 | NS305 | 69 | F | + | 24.64 | 24.15 |
| NS283 | 36 | М | + | 27.18 | 26.91 | NS306 | 42 | F | + | 18.43 | 18.25 |
| NS284 | 54 | М | + | 31.76 | 31.44 | NS307 | 64 | М | + | 20.14 | 19.74 |
| NS285 | 54 | F | + | 24.09 | 24.57 | NS308 | 43 | F | + | 19.34 | 19.34 |
| NS286 | 40 | F | + | 27.34 | 26.79 | NS309 | 32 | М | + | 23.42 | 22.21 |
| NS287 | 42 | F | + | 19.24 | 19.43 | NS310 | 59 | F | + | 24.64 | 24.15 |
| NS288 | 36 | М | + | 27.18 | 26.91 | NS311 | 42 | F | + | 18.43 | 18.25 |
| NS289 | 54 | М | + | 31.76 | 31.44 | NS312 | 24 | М | + | 20.14 | 19.74 |
| NS290 | 71 | М | + | 24.09 | 24.57 | NS313 | 53 | F | + | 19.34 | 19.34 |
| NS291 | 42 | F | + | 27.34 | 26.79 | NS314 | 22 | М | - | >40 | 34.22 |
| NS292 | 45 | F | + | 19.24 | 19.43 | NS315 | 49 | F | + | 24.64 | 24.15 |
| NS293 | 36 | М | + | 27.18 | 26.91 | NS316 | 45 | F | + | 18.43 | 18.25 |

| NS317 | 54 | М | + | 31.76 | 31.44 | NS327 | 64 | M | + | 20.14 | 19.74 |
|-------|----|---|---|-------|-------|-------|----|---|---|-------|-------|
| NS318 | 71 | F | + | 24.09 | 24.57 | NS328 | 63 | F | + | 19.34 | 19.34 |
| NS319 | 42 | F | + | 27.34 | 26.79 | NS329 | 42 | М | - | >40 | 34.21 |
| NS320 | 45 | F | + | 19.24 | 19.43 | NS330 | 29 | F | + | 24.64 | 24.15 |
| NS321 | 36 | М | + | 27.18 | 26.91 | / | / | / | / | / | / |
| NS322 | 15 | F | + | 19.39 | 19.51 | / | / | / | / | / | / |
| NS323 | 71 | F | + | 24.09 | 24.57 | / | / | / | / | / | / |
| NS324 | 42 | F | + | 27.34 | 26.79 | / | / | / | / | / | / |
| NS325 | 45 | F | + | 19.24 | 19.43 | / | / | / | / | / | / |
| NS326 | 36 | М | + | 27.18 | 26.91 | / | / | / | / | / | / |